Impact of IgG3 subclass and C1q-fixing donor-specific hla alloantibodies on rejection and survival in liver transplantation

American Journal of Transplantation

Volumn 15, Issue 4, 2015, Pages 1003-1013

  O'Leary, J G ^a   Kaneku, H ^b   Banuelos, N ^c   Jennings, L W ^a   Klintmalm, G B ^a   Terasaki, P I ^b,c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TERASAKI FOUNDATION LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; COMPLEMENT COMPONENT C1Q; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G;

ADULT; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS; GRAFT REJECTION; IMMUNOLOGY;

ADULT; COMPLEMENT C1Q; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; ISOANTIBODIES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 84925240915     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13153     Document Type: Article

References (47)

1. Terasaki PI, Cai J,. Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 2008; 86: 377-383.
2. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011; 11: 312-319.
3. Snyder LD, Wang Z, Chen DF, et al. Implications for human leukocyte antigen antibodies after lung transplantation: A 10-year experience in 441 patients. Chest 2013; 144: 226-233.
4. Cantarovich D, De Amicis S, Akl A, et al. Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome. Am J Transplant 2011; 11: 2737-2746.
5. Tsai HL, Island ER, Chang JW, et al. Association between donor-specific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation. Transplantation 2011; 92: 709-715.
6. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.
7. Hodges AM, Lyster H, McDermott A, et al. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Transplantation 2012; 93: 650-656.
8. Lobo LJ, Aris RM, Schmitz J, Neuringer IP,. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant 2013; 32: 70-77.
9. de Kort H, Munivenkatappa RB, Berger SP, et al. Pancreas allograft biopsies with positive c4d staining and anti-donor antibodies related to worse outcome for patients. Am J Transplant 2010; 10: 1660-1667.
10. Abu-Elmagd KM, Wu G, Costa G, et al. Preformed and de novo donor specific antibodies in visceral transplantation: Long-term outcome with special reference to the liver. Am J Transplant 2012; 12: 3047-3060.
11. O'Leary JG, Kaneku H, Demetris AJ, et al. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl 2014; 20: 218-227.
12. Iwatsuki S, Rabin BS, Shaw BW, Jr., Starzl TE,. Liver transplantation against T cell-positive warm crossmatches. Transplant Proc 1984; 16: 1427-1429.
13. Gordon RD, Fung JJ, Markus B, et al. The antibody crossmatch in liver transplantation. Surgery 1986; 100: 705-715.
14. Demetris AJ, Isse K,. Tissue biopsy monitoring of operational tolerance in liver allograft recipients. Curr Opin Organ Transplant 2013; 18: 345-353.
15. O'Leary JG, Demetris AJ, Friedman LS, et al. The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant 2014; 14: 779-787.
16. Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: Role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554-562.
17. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
18. O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant. Am J Transplant 2011; 11: 1868-1876.
19. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357-368.
20. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18: 1333-1342.
21. O'Leary JG, Kaneku H, Jennings LW, et al. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013; 19: 973-980.
22. Kaneku H, O'Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13: 1541-1548.
23. O'Leary JG, Gebel HM, Ruiz R, et al. Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant 2013; 13: 954-960.
24. Del Bello A, Congy-Jolivet N, Muscari F, et al. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant 2014; 14: 867-875.
25. Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal, subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307: 283-293.
26. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB,. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984-992.
27. O'Leary JG, Kaneku H, Jennings L, Susskind BM, Terasaki PI, Klintmalm GB,. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. Liver Transpl 2014; 20: 655-663.
28. Schroeder HW, Jr., Cavacini L,. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010; 125: S41-S52.
29. Patel R, Terasaki PI,. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-739.
30. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215-1226.
31. Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant 2013; 32: 98-105.
32. Otten HG, Verhaar MC, Borst HP, et al. The significance of pretransplant donor-specific antibodies reactive with intact or denatured human leucocyte antigen in kidney transplantation. Clin Exp Immunol 2013; 173: 536-543.
33. Freitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 2013; 95: 1113-1119.
34. Fontana M, Moradpour D, Aubert V, Pantaleo G, Pascual M,. Prevalence of anti-HLA antibodies after liver transplantation. Transpl Int 2010; 23: 858-859.
35. Scornik JC, Soldevilla-Pico C, Van der Werf WJ, et al. Susceptibility of liver allografts to high or low concentrations of preformed antibodies as measured by flow cytometry. Am J Transplant 2001; 1: 152-156.
36. Everly MJ, Rebellato LM, Haisch CE, et al. Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients. Transplantation 2014; 97: 494-501.
37. Valenzuela NM, Mulder A, Reed EF,. HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcgammaRs. J Immunol 2013; 190: 6635-6650.
38. Li F, Atz ME, Reed EF,. Human leukocyte antigen antibodies in chronic transplant vasculopathy-mechanisms and pathways. Curr Opin Immunol 2009; 21: 557-562.
39. Zhang X, Reed EF,. Effect of antibodies on endothelium. Am J Transplant 2009; 9: 2459-2465.
40. Valenzuela NM, Reed EF,. Antibodies in transplantation: The effects of HLA and non-HLA antibody binding and mechanisms of injury. Methods Mol Biol 2013; 1034: 41-70.
41. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB,. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012; 16: 12-17.
42. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684-2694.
43. Gombos P, Opelz G, Scherer S, et al. Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Am J Transplant 2013; 13: 2075-2082.
44. Oaks M, Michel K, Sulemanjee NZ, Thohan V, Downey FX,. Practical value of identifying antibodies to cryptic HLA epitopes in cardiac transplantation. J Heart Lung Transplant 2014; 33: 713-720.
45. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47.
46. Cai J, Terasaki PI, Anderson N, Lachmann N, Schonemann C,. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation 2009; 88: 226-230.
47. Grenzi PC, de Marco R, Silva RZ, Campos EF, Gerbase-DeLima M,. Antibodies against denatured HLA class II molecules detected in luminex-single antigen assay. Hum Immunol 2013; 74: 1300-1303.